CRISPRとCas遺伝子の世界市場規模：タイプ別、用途別、エンドユーザー別、地域範囲別および予測

CRISPRとCas遺伝子の市場規模と予測

CRISPRとCas遺伝子の市場規模は、2024年に29億305万米ドルと評価され、2026～2032年にかけて14.97%のCAGRで成長し、2032年には88億6,198万米ドルに達すると予測されています。

CRISPR（Clustered Regularly Interspaced Short Palindromic Repeats）とCas（CRISPR-associated）遺伝子は、革命的な遺伝子編集ツールです。CRISPRは、外来DNAを識別して切断するバクテリアの自然な防御機構であり、Cas9のようなCasタンパク質は、これらの切断を行う分子ハサミとして機能します。この技術は様々な生物に応用できるように開発され、正確な遺伝子配列の改変を可能にしています。遺伝的問題を改善する遺伝子治療、作物の抵抗性や生産性を向上させる農業バイオテクノロジー、病気に関連する遺伝子を標的とした新規治療法の開発など、さまざまな用途があります。

CRISPRとCas遺伝子は広範かつ有望です。この技術の進歩は、遺伝子医薬品を個人の遺伝子プロファイルに合わせてカスタマイズし、最大限の効果を発揮させるという、個別化医療のブレークスルーにつながる可能性が高いです。CRISPRの精度と送達メカニズムの革新は、がんや稀な遺伝子異常などの複雑な疾患の治療における使用を拡大する可能性が高いです。

さらに、CRISPR技術は合成生物学の進歩を促進し、ユニークな機能を持つ改変生物の生産を可能にすると期待されています。倫理的問題と法的枠組みは、こうした進歩を方向づけ、責任ある実施を保証する上で極めて重要です。

CRISPRとCas遺伝子の世界市場力学

世界のCRISPRとCas遺伝子市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

遺伝子異常の有病率の増加：遺伝子異常の有病率の増加は、CRISPRとCas遺伝子市場の主要促進要因です。世界保健機関（WHO）は、およそ1万のヒト疾患がシングルユース性であると報告しています。Global Genes Projectによると、世界中で3億人が希少疾患に苦しんでおり、その大半が遺伝性です。このような大規模な患者集団は、治療の可能性を求めてCRISPRのような遺伝子編集技術に対する高い需要を生み出しています。

ゲノミクス研究への投資増加：CRISPRとCas遺伝子市場は、遺伝子編集技術の進歩を加速させることで前進します。2016～2020年にかけて、米国政府はゲノム研究に38億米ドル以上を融資し、英国の医療研究評議会は2022年に2億ポンドを拠出します。この莫大な資金は、イノベーション、大規模研究、CRISPRベースの医薬品開発を促進し、市場成長の不可欠な要因となっています。

農業と食品生産における応用の拡大：CRISPR技術は、作物の収量を向上させ、世界の食糧需要の増加を満たすために強健な植物品種を開発することにより、農業における飛躍的進歩を推進しています。国連食糧農業機関（FAO）が2050年までに農業生産性が60％増加すると予測している中、CRISPRは広範囲に受け入れられており、20カ国以上で栽培されているCRISPR編集作物を発見した2019年のNature Plants誌の紙製が示しています。CRISPRの農業への応用の拡大は、食糧安全保障と持続可能性を促進し、市場の重要な促進要因となっています。

主要課題

倫理的懸念：CRISPR技術の使用は、特に生殖細胞系列編集とその予期せぬ結果について、重大な倫理的懸念をもたらします。ヒトの胚を編集したり、将来の世代に遺伝する可能性のある改変を加えることは、ヒトの遺伝学に長期的に影響を及ぼす懸念があります。このような倫理的な懸念は、規制の遅れの原因となり、一般大衆の認識にも影響を与え、CRISPRによる解決策への受け入れや投資を減少させる可能性があります。

研究開発のコスト：CRISPRによる技術の開発と商業化には莫大な研究開発コストがかかります。技術革新、規制遵守、臨床検査に関連する高いコストは、中小企業や研究機関が市場で競争することを困難にしかねないです。このコストのかかるハードルは、進歩の妨げとなり、CRISPRベースの治療法の利用可能性を低下させています。

バイオセキュリティのリスク：CRISPR技術が悪用される可能性は、危険な遺伝子改変や生物兵器の開発など、バイオセキュリティ上の懸念を引き起こします。このような懸念を回避するためには、CRISPR技術は責任を持って、適切な保護のもとに利用されなければならないです。バイオセキュリティの懸念に対処することは、この技術の信頼性と安全な使用のために極めて重要です。

主要動向

精度と効率の向上：Cas9のバリエーション強化や新しいCRISPR関連システムの導入を含む最近の動向は、CRISPR技術の精度と効率を大幅に向上させています。これらの開発により、編集精度が向上する一方でオフ対象効果が軽減され、CRISPRは治療応用においてより信頼できるものとなっています。より正確な遺伝子編集への要望は、研究や臨床検査に拍車をかけ、遺伝子異常やその他の疾患の治療に対するこの技術の可能性を高めています。

農業バイオテクノロジーにおける成長：CRISPRは、収量の増加、耐病性、ストレス耐性などの機能が強化された遺伝子組み換え作物の作出に利用されています。遺伝子を正確に変化させることができるこの技術は、農業研究における利用を後押ししています。この動向は、サステイナブル農業技術を促進し、食料安全保障を向上させ、農業部門に大きな関心と投資を生み出しています。

倫理的・規制的枠組みの進展：より明確な倫理原則と規制の枠組みにより、CRISPR技術を責任を持って採用することが容易になっています。規則がより明確になるにつれて、研究者や企業はCRISPRの許容される使用法について理解を深め、臨床診療や商業製品への統合を促進しています。この傾向は、CRISPR市場の信頼と成長を後押ししています。

新規CRISPRシステムの出現：CRISPR/Cas12やCRISPR/Cas13など、Cas9以外の新規CRISPRシステムの発見と開発が進んでいます。これらの革新的なシステムは、オフ対象への影響の少なさやターゲティング能力の向上など、明確な特徴や用途を持っています。これらのシステムの探求は技術革新を促進し、CRISPR技術の可能な応用を広げ、それゆえ市場の成長を支えています。

目次

第1章 世界のCRISPRとCas遺伝子市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• 二次調査
• 一次調査
• 専門家のアドバイス
• 品質チェック
• 最終レビュー
• データの三角測量
• ボトムアップアプローチ
• トップダウンアプローチ
• 調査の流れ
• データソース

第3章 エグゼクティブサマリー

• 概要
• 絶対的収益機会
• 市場の魅力
• 将来の市場機会

第4章 CRISPRとCas遺伝子の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 CRISPRとCas遺伝子の世界市場：タイプ別

• 概要
• DNAフリーのCas
• ベクタベースのCas

第6章 CRISPRとCas遺伝子の世界市場：用途別

• 概要
• ゲノム工学
• 機能ゲノミクス
• 疾患モデル
• その他

第7章 CRISPRとCas遺伝子の世界市場：エンドユーザー別

• 概要
• バイオテクノロジー・製薬企業
• 学術・政府研究機関
• 受託研究機関

第8章 CRISPRとCas遺伝子の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のCRISPRとCas遺伝子市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略
• 企業の地域フットプリント
• 企業の産業フットプリント
• ACEマトリックス

第10章 企業プロファイル

• OriGene Technologies, Inc
• Thermo Fisher Scientific
• Takara Bio Inc.
• Horizon Discovery Ltd.
• Addgene
• Merck KGaA
• Caribou Biosciences, Inc.
• CRISPR THERAPEUTICS
• Editas Medicine
• Mirus Bio LLC.

第11章 主要開発

• 製品の上市/開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

CRISPR And Cas Genes Market Size And Forecast

CRISPR And Cas Genes Market size was valued at USD 2903.05 Million in 2024 and is projected to reach USD 8861.98 Million by 2032, growing at a CAGR of 14.97% from 2026 to 2032.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas (CRISPR-associated) genes are revolutionary genetic editing tools. CRISPR is a natural defense mechanism in bacteria that identifies and cuts foreign DNA, while Cas proteins, such as Cas9, operate as molecular scissors to perform these cuts. This technique has been developed for application in a wide range of organisms, allowing for precise genetic sequence modifications. Gene therapy to rectify genetic problems, agricultural biotechnology to improve crop resistance and productivity, and the creation of novel treatments by targeting disease-associated genes are among the various uses.

The CRISPR and Cas genes are extensive and promising. Advances in this technique are likely to lead to breakthroughs in personalized medicine, with genetic medicines customized to individual genetic profiles for maximum efficacy. Innovations in CRISPR precision and delivery mechanisms are likely to expand its use in the treatment of complicated diseases such as cancer and rare genetic abnormalities.

Furthermore, CRISPR technology is expected to propel advances in synthetic biology, allowing the production of modified creatures with unique functions. Ethical issues and legal frameworks will be critical in directing these advancements and guaranteeing their responsible implementation.

Global CRISPR And Cas Genes Market Dynamics

The key market dynamics that are shaping the global CRISPR And Cas Genes Market include:

Key Market Drivers:

Increasing Prevalence of Genetic Disorders: The increasing prevalence of genetic abnormalities is a primary driver of the CRISPR And Cas Genes Market. The World Health Organization (WHO) reports that roughly 10,000 human disorders are monogenic. According to the Global Genes Project, 300 million people worldwide suffer from rare diseases, the majority of which are hereditary. This large patient population generates a high demand for gene-editing technologies such as CRISPR for possible treatments.

Rising Investments in Genomics Research: The CRISPR And Cas Genes Market forward by speeding advances in gene-editing technologies. From 2016 to 2020, the US government financed more than $3.8 billion on genomics research, with the UK's Medical Research Council committing £200 million in 2022. This enormous funding promotes innovation, large-scale studies, and the development of CRISPR-based medicines, making it an essential factor in market growth.

Expanding Applications in Agriculture and Food Production: CRISPR technology is driving breakthroughs in agriculture by boosting crop yields and developing robust plant varieties to fulfill rising global food demand. With the Food and Agriculture Organization (FAO) anticipating a 60% increase in agricultural productivity by 2050, CRISPR is being extensively embraced, as indicated by a 2019 article in Nature Plants, which found CRISPR-edited crops grown in over 20 nations. This growing application of CRISPR in agriculture promotes food security and sustainability, making it an important driver in the market.

Key Challenges:

Ethical Concerns: The use of CRISPR technology presents significant ethical concerns, notably about germline editing and its unintended consequences. Editing human embryos or making alterations that may be inherited by future generations raises concerns about the implications over time for human genetics. These ethical considerations can cause regulatory delays and influence public perception, reducing acceptance and investment in CRISPR-based solutions.

Cost of Research and Development: Developing and commercializing CRISPR-based technologies incurs enormous R&D costs. The high costs associated with innovation, regulatory compliance, and clinical trials can make it difficult for smaller enterprises and research institutes to compete in the market. This costly hurdle hinders progress and reduces the availability of CRISPR-based therapies.

Biosecurity Risks: The possible misuse of CRISPR technology raises biosecurity concerns, such as the development of risky genetic changes or bioweapons. To avoid these concerns, CRISPR technology must be utilized responsibly and with proper protections in place. Addressing biosecurity concerns is critical for the technology's credibility and safe use.

Key Trends:

Precision and Efficiency Advancements: Recent developments, including enhancements in Cas9 variations and the introduction of new CRISPR-associated systems, have considerably improved CRISPR technology's precision and efficiency. These developments lessen off-target effects while increasing editing accuracy, making CRISPR more trustworthy for therapeutic applications. The desire for more precise gene editing is fueling research and clinical trials, increasing the technology's promise for treating genetic abnormalities and other diseases.

Growth in Agricultural Biotechnology: CRISPR is being used to generate genetically modified crops with enhanced features such as increased yield, disease resistance, and stress tolerance. The technology's capacity to make precise genetic changes is pushing its use in agricultural research. This trend promotes sustainable farming techniques and improves food security, generating major interest and investment in the agriculture sector.

Advancement in Ethical and Regulatory Frameworks: Clearer ethical principles and regulatory frameworks are making it easier to employ CRISPR technology responsibly. As rules become more defined, researchers and businesses acquire a greater understanding of the acceptable use of CRISPR, facilitating its integration into clinical practice and commercial products. This tendency is boosting confidence and growth in the CRISPR market.

Emergence of Novel CRISPR Systems: The discovery and development of novel CRISPR systems beyond Cas9, such as CRISPR/Cas12 and CRISPR/Cas13, is ongoing. These innovative systems have distinct traits and applications, including fewer off-target impacts and increased targeting capabilities. Exploration of these systems drives innovation and broadens the possible applications of CRISPR technology, hence supporting market growth.

Global CRISPR And Cas Genes Market Regional Analysis

Here is a more detailed regional analysis of the global CRISPR And Cas Genes Market:

North America:

North America remains a dominant player in the CRISPR And Cas Genes Market, owing to its strong research infrastructure and advanced biotechnology sector. The region's best research institutes and universities are critical to CRISPR innovation, with NIH funding increasing from USD 5.1 Million in 2011 to more than USD 603 Million in 2020, representing an unparalleled 11,725% growth. This flood of funding has resulted in a 27% annual increase in CRISPR-related publications from North American institutions, as reported by PubMed in 2022. Complementing this, North America's well-established biotechnology industry, which includes over 6,500 biotech firms in the United States, with around 12% focusing on gene editing, drives significant progress.

The region's favorable regulatory framework also helps to advance CRISPR research and commercialization. The FDA has accepted 23 Investigational New Drug (IND) applications for CRISPR-based therapies as of 2024, a 53% increase over 2020. Since 2019, the Regenerative Medicine Advanced Therapy (RMAT) designation has advanced the approval of five CRISPR-based therapeutics.

The growing number of active CRISPR-related clinical trials, which will reach 152 in North America by September 2024, a 36% increase over the previous year, illustrates CRISPR's expanding therapeutic applicability, notably in oncology. These factors contribute to North America's leadership and continuous innovation in the CRISPR And Cas Genes Market.

Asia Pacific:

The CRISPR And Cas Genes Market in Asia Pacific is expanding rapidly, owing to significant investments, increased research activity, and a big population base. Governments in the area are making considerable expenditures in biotechnology and healthcare, with biotechnology investments increasing by 32% between 2018 and 2022, according to the Asia Pacific Economic Cooperation. China has committed USD 9.2 Billion to its precision medicine project, which includes significant funding for CRISPR technology, while Japan's genome editing consumption has increased by 41% between 2019 and 2024. This funding backing has sped up the development of CRISPR-based solutions and technologies.

The Asia Pacific area has strong financial backing, vigorous research activity, and a large population, all of which fuel demand for CRISPR applications. Research institutes have dramatically boosted their contributions to CRISPR investigations, with Asia Pacific publications increasing by 28% annually between 2018 and 2022. The region's massive population, predicted to reach 4.7 billion by 2025, opens up numerous prospects for CRISPR in healthcare and agriculture. For instance, 12 Asian countries are developing CRISPR-edited crops, with field trials increasing by 45% between 2020 and 2024. The number of CRISPR-related clinical trials in Asia Pacific increased by 140% between 2019 and 2024, demonstrating the region's growing importance in worldwide CRISPR breakthroughs and applications.

Global CRISPR And Cas Genes Market: Segmentation Analysis

The Global CRISPR And Cas Genes Market is Segmented on the basis of Type, Application, End-User, And Geography.

CRISPR And Cas Genes Market, By Type

• DNA-Free Cas
• Vector-Based Cas

Based on Type, the market is bifurcated into DNA-free Cas and Vector-based Cas. The CRISPR and Cas gene market is currently dominated by vector-based Cas systems, which use viral vectors to deliver the Cas gene to cells. This method has been widely utilized due to its effectiveness and versatility. DNA-free Cas systems, which use non-viral delivery techniques, are becoming the most rapidly developing sector. These systems have advantages such as fewer off-target effects and larger safety, making them appealing for therapeutic applications. As research and development in DNA-free Cas delivery progresses, it is projected to capture considerable market share in the years ahead.

CRISPR And Cas Genes Market, By Application

• Genome Engineering
• Functional Genomics
• Disease Models

Based on Application, the market is segmented into Genome Engineering, Functional Genomics, and Disease Models. The CRISPR And Cas Genes Market is currently dominated by genome engineering applications, which include changing organisms' genetic code for a variety of reasons. This segment has grown significantly due to its ability to solve a wide range of difficulties, such as disease treatment, crop improvement, and biofuel generation. Functional genomics, which examines gene function and connections, is emerging as the most rapidly increasing segment. As researchers develop a better grasp of gene biology, functional genomics applications grow, increasing demand for CRISPR-based tools and techniques.

CRISPR And Cas Genes Market, By End-User

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Contract Research Organizations

Based on End-User, the market is segmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. Biotechnology and pharmaceutical businesses now dominate the CRISPR and Cas gene market, using this technology for drug discovery, development, and therapeutic applications. These firms have significant resources and competence in translating CRISPR research into commercial goods. Academic institutions and government research institutes are emerging as the most rapidly rising area. These institutions play an important role in fundamental research, promoting innovation, and improving the area of CRISPR. Their findings are frequently used to develop commercial applications, making them important contributors to market growth.

Key Players

The "Global CRISPR And Cas Genes Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are OriGene Technologies, Inc., Thermo Fisher Scientific, Takara Bio, Inc., Horizon Discovery Ltd., Addgene, Merck KGaA, Caribou Biosciences, Inc., CRISPR therapeutics, Editas Medicine and Mirus Bio LLC. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• CRISPR And Cas Genes Market Recent Developments
• In June 2024, DNA nanobots, a biotechnology business, stated that it completed gene editing technology developed at the University of California (UC) Berkeley. The licensed intellectual property allows for the folding of genes into their own delivery devices, in conjunction with CRISPR-Cas, to provide very efficient non-viral gene delivery.
• In April 2024, Caszyme, a biotech company based in Lithuania that develops CRISPR gene-editing technology, plans to construct a new facility. The expansion seeks to help create non-complementary competencies to fulfill the growing demand for gene-editing-based systems and products across Asia, Europe, and the United States.
• In November 2022, Researchers at the Massachusetts Institute of Technology developed PASTE, a new CRISPR-based technology that inserts huge DNA sequences at targeted places in cells. The approach has the potential to treat a wide range of diseases caused by defective genes.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CRISPR AND CAS GENES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 2.1 Data mining
• 2.2 Secondary research
• 2.3 Primary research
• 2.4 Subject matter expert advice
• 2.5 Quality check
• 2.6 Final review
• 2.7 Data triangulation
• 2.8 Bottom-up approach
• 2.9 Top-down approach
• 2.10 Research flow
• 2.11 Data sources

3 EXECUTIVE SUMMARY

• 3.1 Overview
• 3.2 Absolute $ Opportunity
• 3.3 Market attractiveness
• 3.4 Future Market Opportunities

4 GLOBAL CRISPR AND CAS GENES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CRISPR AND CAS GENES MARKET, BY TYPE

• 5.1 Overview
• 5.2 DNA-free Cas
• 5.3 Vector-based Cas

6 GLOBAL CRISPR AND CAS GENES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Genome Engineering
• 6.3 Functional Genomics
• 6.4 Disease Models
• 6.5 Others

7 GLOBAL CRISPR AND CAS GENES MARKET, BY END-USER

• 7.1 Overview
• 7.2 Biotechnology & Pharmaceutical Companies
• 7.3 Academic & Government Research Institutes
• 7.4 Contract Research Organizations

8 GLOBAL CRISPR AND CAS GENES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL CRISPR AND CAS GENES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies
• 9.4 Company Regional Footprint
• 9.5 Company Industry Footprint
• 9.6 ACE Matrix

10 COMPANY PROFILES

• 10.1 OriGene Technologies, Inc
  • 10.1.1 Company Overview
  • 10.1.2 Company Insights
  • 10.1.3 Business Breakdown
  • 10.1.4 Product Benchmarking
  • 10.1.5 Key Developments
  • 10.1.6 Winning Imperatives
  • 10.1.7 Current Focus & Strategies
  • 10.1.8 Threat from Competition
  • 10.1.9 SWOT Analysis
• 10.2 Thermo Fisher Scientific
  • 10.2.1 Company Overview
  • 10.2.2 Company Insights
  • 10.2.3 Business Breakdown
  • 10.2.4 Product Benchmarking
  • 10.2.5 Key Developments
  • 10.2.6 Winning Imperatives
  • 10.2.7 Current Focus & Strategies
  • 10.2.8 Threat from Competition
  • 10.2.9 SWOT Analysis
• 10.3 Takara Bio Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Insights
  • 10.3.3 Business Breakdown
  • 10.3.4 Product Benchmarking
  • 10.3.5 Key Developments
  • 10.3.6 Winning Imperatives
  • 10.3.7 Current Focus & Strategies
  • 10.3.8 Threat from Competition
  • 10.3.9 SWOT Analysis
• 10.4 Horizon Discovery Ltd.
  • 10.4.1 Company Overview
  • 10.4.2 Company Insights
  • 10.4.3 Business Breakdown
  • 10.4.4 Product Benchmarking
  • 10.4.5 Key Developments
  • 10.4.6 Winning Imperatives
  • 10.4.7 Current Focus & Strategies
  • 10.4.8 Threat from Competition
  • 10.4.9 SWOT Analysis
• 10.5 Addgene
  • 10.5.1 Company Overview
  • 10.5.2 Company Insights
  • 10.5.3 Business Breakdown
  • 10.5.4 Product Benchmarking
  • 10.5.5 Key Developments
  • 10.5.6 Winning Imperatives
  • 10.5.7 Current Focus & Strategies
  • 10.5.8 Threat from Competition
  • 10.5.9 SWOT Analysis
• 10.6 Merck KGaA
  • 10.6.1 Company Overview
  • 10.6.2 Company Insights
  • 10.6.3 Business Breakdown
  • 10.6.4 Product Benchmarking
  • 10.6.5 Key Developments
  • 10.6.6 Winning Imperatives
  • 10.6.7 Current Focus & Strategies
  • 10.6.8 Threat from Competition
  • 10.6.9 SWOT Analysis
• 10.7 Caribou Biosciences, Inc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Insights
  • 10.7.3 Business Breakdown
  • 10.7.4 Product Benchmarking
  • 10.7.5 Key Developments
  • 10.7.6 Winning Imperatives
  • 10.7.7 Current Focus & Strategies
  • 10.7.8 Threat from Competition
  • 10.7.9 SWOT Analysis
• 10.8 CRISPR THERAPEUTICS
  • 10.8.1 Company Overview
  • 10.8.2 Company Insights
  • 10.8.3 Business Breakdown
  • 10.8.4 Product Benchmarking
  • 10.8.5 Key Developments
  • 10.8.6 Winning Imperatives
  • 10.8.7 Current Focus & Strategies
  • 10.8.8 Threat from Competition
  • 10.8.9 SWOT Analysis
• 10.10 Editas Medicine
  • 10.9.1 Company Overview
  • 10.9.2 Company Insights
  • 10.9.3 Business Breakdown
  • 10.9.4 Product Benchmarking
  • 10.9.5 Key Developments
  • 10.9.6 Winning Imperatives
  • 10.9.7 Current Focus & Strategies
  • 10.9.8 Threat from Competition
  • 10.9.9 SWOT Analysis
• 10.10 Mirus Bio LLC.
  • 10.10.1 Company Overview
  • 10.10.2 Company Insights
  • 10.10.3 Business Breakdown
  • 10.10.4 Product Benchmarking
  • 10.10.5 Key Developments
  • 10.10.6 Winning Imperatives
  • 10.10.7 Current Focus & Strategies
  • 10.10.8 Threat from Competition
  • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 APPENDIX

• 12.1 Related Research